News from janssen pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Oct 18, 2010, 16:06 ET

Acetato de abiraterona melhorou significativamente a sobrevida geral de pacientes com câncer de próstata metastático avançado

Os resultados de uma análise interina pré-especificada do estudo em Fase 3 aleatório e controlado por placebo, COU-AA-301,...

Oct 18, 2010, 16:01 ET

El acetato de abiraterone mejoró significativamente la supervivencia general en pacientes con cáncer de próstata metastásico avanzado

Los resultados de un análisis provisional preespecificado de un ensayo en Fase 3 aleatorio y controlado por placebo, COU-AA-301, muestran que...

Sep 27, 2010, 08:30 ET

Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients With Chronic Low Back Pain

Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients...

Sep 24, 2010, 15:38 ET

2010 Renewable Energy Milestone: Janssen Turns On New Jersey's Largest Solar Energy System Sept. 23

With the flip of a switch on Thursday, the largest solar panel array in New Jersey will come to life on the campus of Janssen, Division of...

Aug 30, 2010, 15:37 ET

Pivotal Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Osteoarthritis Knee Pain

Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients...

Jun 28, 2010, 10:00 ET

Ortho-McNeil-Janssen Pharmaceuticals, Inc. Announces Oncology Research Collaboration Agreement with the Koch Institute for Integrative Cancer Research at MIT

Ortho-McNeil-Janssen Pharmaceuticals, Inc. today announced the signing of a five-year collaboration agreement with the David H. Koch Institute for...

May 25, 2010, 16:00 ET
A F MCNEIL PEDIATRICS LOGO MCNEIL PEDIATRICS LOGO

McNeil Pediatrics logo. (PRNewsFoto/McNeil Pediatrics, Division of Ortho-McNeil-Janssen, Inc.)[TK]
 TITUSVILLE, NJ UNITED STATES
 02/11/2010

New Data Analyses of CONCERTA(R) Efficacy on ADHD in the Classroom

Turning in assignments, following instructions and focusing on learning something new are among the daily classroom challenges for children with...

May 24, 2010, 08:00 ET

New Survey Reveals Positive and Respectful Relationship Among Psychiatrists, Patients With Schizophrenia and Their Caregivers

According to a new survey sponsored by Janssen,® Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, 80 percent of patients with...

May 24, 2010, 08:00 ET

New Data on INVEGA(R) SUSTENNA(R) and RISPERDAL(R) CONSTA(R) for Schizophrenia to be Presented at Major Psychiatry Meeting

New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on...

May 07, 2010, 08:00 ET

Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting

A post-hoc analysis of a Phase 3 safety study demonstrated that NUCYNTA® (tapentadol) tablets were associated with a lower incidence of...

Apr 29, 2010, 12:37 ET

Ortho-McNeil-Janssen Pharmaceuticals, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities

Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI) today announced an agreement with the U.S. Attorney's Office for the District of Massachusetts,...

Dec 10, 2009, 07:57 ET

Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection

Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new...

Dec 04, 2009, 07:00 ET

Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment

Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the...

Nov 19, 2009, 14:07 ET

AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals Inc.: Getting Ready for Cold and Flu Season

As the seasons change, another season of coughs and running noses is here. Here's more on preparing yourself. Listen to this report from...

Nov 16, 2009, 08:00 ET

National Expressions of Courage Art Contest Unveils Stories of Inspiration

Epilepsy and seizures affect nearly 3 million Americans of all ages and in 70 percent of new cases, no cause is apparent. Those who live...

Nov 11, 2009, 08:00 ET

Analysis Underscores Financial Burden of Mental Illness On Criminal Justice and Health Care Systems

Results from a large, retrospective analysis of inmates with a serious mental illness (SMI) underscores the financial burden of mental illness on...

Aug 21, 2009, 17:15 ET

FDA Issues Complete Response Letter for Carisbamate

The U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for carisbamate, an...

Aug 03, 2009, 08:09 ET

Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia

The U.S. Food and Drug Administration approved INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) extended-release injectable suspension for the...

May 18, 2009, 08:00 ET

FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder

RISPERDAL(R) CONSTA(R) is the First and Only Long-Acting Antipsychotic Therapy Available for Bipolar I Disorder Janssen(R), Division of...

Apr 22, 2009, 08:00 ET

Video: Adults 'Facing' ADHD: ADHD Allies(TM) Offers Unique Online Community for Adults with ADHD on New Facebook(R) Page

Although Attention Deficit Hyperactivity Disorder (ADHD) is a condition commonly thought of as only affecting children, for nearly 9 million adults...